Abstract 4232
Background
Pediatrics and AYA patients with cancer care often reported to receive high intensity medical care at the end-of-life. Especially, one study showed that Taiwanese children are more likely to receive high intensity care within one month from death than Canadian children. In this study, we investigate the current condition of end-of-life care for pediatrics, AYA patients who died at the hospital in Japan.
Methods
Using a multicenter administrative claims database, we identified patients with cancer aged 17 years or younger who died in hospital between July 2012 and March 2017 from 303 acute care hospitals in Japan. Patients’ data included age, gender, diagnosis, length of stay (LOS), use of opioids, the factors related to high-intensity end-of-life care (H-EOL), which comprised factors as follows; iv chemotherapy within 14 days from death, intensive care unit admission, more than one emergency department (ED) visit, more than 14 days hospital admission, and respiratory ventilation within one month from death.
Results
A total of 106 patients who died in 47 hospitals were included. The median age was 9 (0-17) years old and 57 patients (54%) were boys. Patients had brain tumor (n = 37), solid tumor (n = 30), hematologic malignancy (n = 25), other (n = 14). The average LOS was 60 (0-428 days). Fifty-five patients received opioids within 2weeks before their death. Ten patients received home medical care treatment before their death in the hospitals. Iv chemotherapy within 14 days from death was 25 patients (23.6%), intensive care unit admission within one month from death was 17 patients (16.0%), more than one ED visit within one month from death was 70 patients (66.0%), more than 14 days hospital admission was 69 patients (65.0%), and respiratory ventilation within one month from death was 20 patients (18.9%). Forty patients received one, 49 patients received two, 10 patients received three, 5 patients received four H-EOL care factors, respectively. Totally, 98% of patients had at least one H-EOL care factor.
Conclusions
Our study clarified the current situation of end-of-life care in the field of pediatrics, AYA with cancer. The proportion of H-EOL care in Japan is similar to that in Taiwan, and higher compared with that in Canada.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5128 - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Presenter: Adrien Dixmier
Session: Poster Display session 1
Resources:
Abstract
2066 - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)
Presenter: Denis Talbot
Session: Poster Display session 1
Resources:
Abstract
5919 - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States
Presenter: David Stenehjem
Session: Poster Display session 1
Resources:
Abstract
3368 - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Presenter: Nikolaj Frost
Session: Poster Display session 1
Resources:
Abstract
3775 - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
3926 - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative
Presenter: Michael Snee
Session: Poster Display session 1
Resources:
Abstract
5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Presenter: Karim Amrane
Session: Poster Display session 1
Resources:
Abstract
1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients
Presenter: Teppei Sugano
Session: Poster Display session 1
Resources:
Abstract
2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Presenter: Yosuke Kawashima
Session: Poster Display session 1
Resources:
Abstract
2739 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohe
Session: Poster Display session 1
Resources:
Abstract